Sami Corwin
Stock Analyst at William Blair
(n/a)
# 4,719
Out of 4,944 analysts
12
Total ratings
n/a
Success rate
-49.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | n/a | $20.40 | - | 1 | Jun 20, 2025 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Outperform | $65 | $28.97 | +124.37% | 1 | May 28, 2025 | |
| NKTX Nkarta | Downgrades: Market Perform | n/a | $2.21 | - | 1 | May 15, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Market Perform | n/a | $4.46 | - | 2 | Jan 30, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $0.45 | - | 1 | Dec 23, 2024 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $0.86 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $21.11 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $15.19 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $57.33 | +30.82% | 1 | May 30, 2023 | |
| LEGN Legend Biotech | Initiates: Market Perform | n/a | $36.93 | - | 1 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $66 | $14.60 | +352.05% | 1 | Oct 27, 2021 |
Sarepta Therapeutics
Jun 20, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $20.40
Upside: -
Ultragenyx Pharmaceutical
May 28, 2025
Initiates: Outperform
Price Target: $65
Current: $28.97
Upside: +124.37%
Nkarta
May 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.21
Upside: -
CARGO Therapeutics
Jan 30, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.46
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.45
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.86
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $21.11
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $15.19
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $57.33
Upside: +30.82%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $36.93
Upside: -
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $14.60
Upside: +352.05%